FactorV C1149G and 5609–10INSCGTGGTT causing factor V deficiency: Molecular characterization by in-vitro expression

2007 ◽  
Vol 98 (09) ◽  
pp. 683-685 ◽  
Author(s):  
Qiu-Lan Ding ◽  
Qi-Hua Fu ◽  
Xiao-Hong Cai ◽  
Xue-Feng Wang ◽  
Hong-Li Wang
Haemophilia ◽  
2018 ◽  
Vol 24 (4) ◽  
pp. 648-656 ◽  
Author(s):  
C. Bulato ◽  
C. Novembrino ◽  
M. Boscolo Anzoletti ◽  
L. Spiezia ◽  
S. Gavasso ◽  
...  
Keyword(s):  
Factor V ◽  

Blood ◽  
2013 ◽  
Vol 122 (23) ◽  
pp. 3825-3831 ◽  
Author(s):  
Francesca Nuzzo ◽  
Claudia Radu ◽  
Marco Baralle ◽  
Luca Spiezia ◽  
Tilman M. Hackeng ◽  
...  

Key Points Homozygosity for the F5 c.1296+268A>G splicing mutation causes life-threatening factor V deficiency. Mutation-specific antisense molecules can correct this splicing defect and restore factor V synthesis in the patient’s megakaryocytes.


2011 ◽  
Vol 106 (08) ◽  
pp. 296-303 ◽  
Author(s):  
Ilaria Guella ◽  
Elvezia Maria Paraboschi ◽  
Willem A. van Schalkwyk ◽  
Rosanna Asselta ◽  
Stefano Duga

SummaryFactor V (FV) deficiency is a rare autosomal recessive haemorrhagic disorder associated with moderate to severe bleeding symptoms. Conventional mutational screening leads to a complete molecular genetic diagnosis only in about 80–90% of cases. Large gene rearrangements, which could explain at least part of the “missing alleles” have not been reported so far in FV-deficient patients. In this work, we investigated a family with hereditary FV deficiency, in which the proband is compound heterozygous for a 205-Kb deletion, involving the first seven exons of F5, and the entire selectin P, L, and E genes, and for a novel splicing mutation (IVS12+5G>A). The deletion breakpoints, determined by using a combination of semi-quantitative real-time PCR and long PCR assays, occurred within AluY repeat sequences, suggesting an Alu-mediated unequal homologous recombination as the mechanism responsible for the deletion. The in vitro characterisation of the IVS12+5G>A mutation demonstrated that this mutation causes the skipping of exon 12 and the activation of a cryptic splice site. Low levels of residual wild-type splicing were also detectable, in agreement with the notion that the complete absence of FV may be not compatible with life.


2007 ◽  
Vol 86 (5) ◽  
pp. 407-413 ◽  
Author(s):  
Keiko Shinozawa ◽  
Kagehiro Amano ◽  
Takashi Suzuki ◽  
Asashi Tanaka ◽  
Kenji Iijima ◽  
...  

Haematologica ◽  
2008 ◽  
Vol 93 (10) ◽  
pp. 1505-1513 ◽  
Author(s):  
C. Dall'Osso ◽  
I. Guella ◽  
S. Duga ◽  
N. Locatelli ◽  
E. M. Paraboschi ◽  
...  

1998 ◽  
Vol 79 (05) ◽  
pp. 1041-1047 ◽  
Author(s):  
Kathleen M. Donnelly ◽  
Michael E. Bromberg ◽  
Aaron Milstone ◽  
Jennifer Madison McNiff ◽  
Gordon Terwilliger ◽  
...  

SummaryWe evaluated the in vivo anti-metastatic activity of recombinant Ancylostoma caninum Anticoagulant Peptide (rAcAP), a potent (Ki = 265 pM) and specific active site inhibitor of human coagulation factor Xa originally isolated from bloodfeeding hookworms. Subcutaneous injection of SCID mice with rAcAP (0.01-0.2 mg/mouse) prior to tail vein injection of LOX human melanoma cells resulted in a dose dependent reduction in pulmonary metastases. In order to elucidate potential mechanisms of rAcAP’s anti-metastatic activity, experiments were carried out to identify specific interactions between factor Xa and LOX. Binding of biotinylated factor Xa to LOX monolayers was both specific and saturable (Kd = 15 nM). Competition experiments using antibodies to previously identified factor Xa binding proteins, including factor V/Va, effector cell protease receptor-1, and tissue factor pathway inhibitor failed to implicate any of these molecules as significant binding sites for Factor Xa. Functional prothrombinase activity was also supported by LOX, with a half maximal rate of thrombin generation detected at a factor Xa concentration of 2.4 nM. Additional competition experiments using an excess of either rAcAP or active site blocked factor Xa (EGR-Xa) revealed that most of the total factor Xa binding to LOX is mediated via interaction with the enzyme’s active site, predicting that the vast majority of cell-associated factor Xa does not participate directly in thrombin generation. In addition to establishing two distinct mechanisms of factor Xa binding to melanoma, these data raise the possibility that rAcAP’s antimetastatic effect in vivo might involve novel non-coagulant pathways, perhaps via inhibition of active-site mediated interactions between factor Xa and tumor cells.


1999 ◽  
Vol 82 (11) ◽  
pp. 1462-1468 ◽  
Author(s):  
José Fernández ◽  
Jari Petäjä ◽  
John Griffin

SummaryUnfractionated heparin potentiates the anticoagulant action of activated protein C (APC) through several mechanisms, including the recently described enhancement of proteolytic inactivation of factor V. Possible anticoagulant synergism between APC and physiologic glycosaminoglycans, pharmacologic low molecular weight heparins (LMWHs), and other heparin derivatives was studied. Dermatan sulfate showed potent APC-enhancing effect. Commercial LMWHs showed differing abilities to promote APC activity, and the molecular weight of LMWHs correlated with enhancement of APC activity. Degree of sulfation of the glycosaminoglycans influenced APC enhancement. However, because dextran sulfates did not potentiate APC action, the presence of sulfate groups per se on a polysaccharide is not sufficient for APC enhancement. As previously for unfractionated heparin, APC anticoagulant activity was enhanced by glycosaminoglycans when factor V but not factor Va was the substrate. Thus, dermatan sulfate and LMWHs exhibit APC enhancing activity in vitro that could be of physiologic and pharmacologic significance.


Sign in / Sign up

Export Citation Format

Share Document